Hundreds of updates were provided on clinical trials and preclinical research at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.
After touting positive Phase III results at the American Society of Hematology’s annual meeting, the U.S. FDA placed a clinical hold on uniQure”s hemophilia B treatment AMT-061 due to a patient developing liver cancer.
The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5 with numerous presentations, abstracts and posters.
Roche Group member Genentech announced that new data from the pivotal Phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta (venetoclax)-based combinations in certain people with chronic lymphocytic leukemia (CLL) and provide more evidence on the potential value of minimal residual disease.
The Janssen Pharmaceutical Companies of Johnson & Johnson has a presence in more than 80 of the hematology studies presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition in December.
South San Francisco-based Allogene Therapeutics released some early data from the company’s UNIVERSAL clinical trial of ALLO-715 for relapsed/refractory multiple myeloma.
Ahead of a planned Phase III study, Pfizer and Sangamo Therapeutics released follow-up data from its Phase I/II Alta study in hemophilia A that showed an investigational gene therapy treatment provided blood-clotting activity levels for more than one year.
South San Francisco-based Global Blood Therapeutics struck a deal with Syros Pharmaceuticals that is worth up to $375 million to discover, develop and commercialize novel therapies for the two types of blood disorders.
Positive results were reported from a pivotal Phase III trial assessing the safety and efficacy of Sanofi’s sutimlimab in people with primary cold agglutinin disease (CAD).
Hundreds of studies and results were presented at the 61st American Society of Hematology (ASH) Annual Meeting.
